Prevalence of cognitive impairment before prostate cancer treatment

• Autor(a) principal: Araújo, Natália
• Data de Publicação: 2022
• Outros Autores: Costa, Adriana, Lopes, Catarina, Lopes-Conceição, Luisa, Ferreira, Augusto, Carneiro, Filipa, Oliveira, Jorge, Morais, Samantha, Figueiredo, Luís Pacheco, Ruano, Luis, Cruz, Vítor Tedim, Pereira, Susana, Lunet, Nuno
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/1822/78969
• topic: Prostate cancer; Prevalence study; Cognitive dysfunction/epidemiology; Neuropsychological test; cognitive dysfunction; epidemiology; Science & Technology

Cognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age- and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (<i>n</i> = 351 men aged ≥40 years, evaluated in 2013–2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age- and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer.